Drugs / PMC-309
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05957081 | Jan 2024 → Oct 2029 expected | — | PharmAbcine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMC-309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05957081 ↗ |
| Route | Intravenous | “PMC-309 will be administered intravenously.” NCT05957081 ↗ |